KIT as a therapeutic target in metastatic melanoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Melanoma
  • Piperazines
  • Proto-Oncogene Proteins c-kit
  • Pyrimidines
  • Skin Neoplasms

abstract

  • Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients. Responses may be limited to tumors harboring KIT alterations of proven functional relevance. Trial Registration clinicaltrials.gov Identifier: NCT00470470.

publication date

  • June 8, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3986039

Digital Object Identifier (DOI)

  • 10.1001/jama.2011.746

PubMed ID

  • 21642685

Additional Document Info

start page

  • 2327

end page

  • 34

volume

  • 305

number

  • 22